Scholarlink

<p>Long-acting injectable Cabotegravir (CAB-LA) received regulatory approval in Australia but is not available for prevention. This online cross-sectional study of 1,687 gay, bisexual, and other men who have sex with men (GBMSM) in Australia between May to November 2022 assessed interest in and preference for CAB-LA and other existing and hypothetical PrEP options. When asked for their top preference, the most preferred options were monthly oral pills (28.2%), followed by six-monthly injections (24.6%), removable implants (15.5%), daily oral (14.0%), event-driven oral (13.4%), and CAB-LA (3.9%). Common potential reasons to like CAB-LA included not having to remember to take pills (65.0%), protection against HIV (63.8%), and longer-term protection compared to other methods (46.9%). Common concerns included not knowing enough about CAB-LA yet (46.7%), cost may be unaffordable (44.6%), and potential side effects (<i>n</i> = 547, 32.4%). There were 654 (40.3%) participants who would want long-acting PrEP injections if they could switch back and forth between other forms of PrEP. Interest in using CAB-LA was associated with younger age (aOR = 0.98, 95%CI = 0.97–0.99), having ever taken PrEP (aOR = 2.06, 95%CI = 1.48–2.88), having 11 or more sexual partners in the last 6 months (aOR = 1.65, 95%CI = 1.25–2.17), believing some friends or sex partners are taking PrEP (aOR = 1.58, 95%CI = 1.18–2.11), reporting wanting to try CAB-LA if it was more effective than oral PrEP (aOR = 2.05, 95%CI = 1.48–2.86), or believing CAB-LA is more effective than event-driven oral PrEP (aOR = 1.48, 95%CI = 1.10–1.99). This analysis demonstrated Australian GBMSM have a diverse range of preferences of PrEP options, and access to newer options is needed to increase HIV prevention coverage.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessing Demand for Long-Acting Injectable PrEP and Emerging PrEP Options for HIV Prevention in Australia: Results from a Cross-Sectional Survey of Men Who have Sex with Men

  • 期刊论文

  • 发表日期：

    2025年11月17日

查看全文
  • Curtis Chan,
  • Heather-Marie Schmidt,
  • Jason J. Ong,
  • Warittha Tieosapjaroen,
  • Andrew E. Grulich,
  • Nittaya Phanuphak,
  • Edwina J. Wright,
  • Bella Bushby,
  • Lei Zhang,
  • Benjamin R. Bavinton

摘要

Long-acting injectable Cabotegravir (CAB-LA) received regulatory approval in Australia but is not available for prevention. This online cross-sectional study of 1,687 gay, bisexual, and other men who have sex with men (GBMSM) in Australia between May to November 2022 assessed interest in and preference for CAB-LA and other existing and hypothetical PrEP options. When asked for their top preference, the most preferred options were monthly oral pills (28.2%), followed by six-monthly injections (24.6%), removable implants (15.5%), daily oral (14.0%), event-driven oral (13.4%), and CAB-LA (3.9%). Common potential reasons to like CAB-LA included not having to remember to take pills (65.0%), protection against HIV (63.8%), and longer-term protection compared to other methods (46.9%). Common concerns included not knowing enough about CAB-LA yet (46.7%), cost may be unaffordable (44.6%), and potential side effects (n = 547, 32.4%). There were 654 (40.3%) participants who would want long-acting PrEP injections if they could switch back and forth between other forms of PrEP. Interest in using CAB-LA was associated with younger age (aOR = 0.98, 95%CI = 0.97–0.99), having ever taken PrEP (aOR = 2.06, 95%CI = 1.48–2.88), having 11 or more sexual partners in the last 6 months (aOR = 1.65, 95%CI = 1.25–2.17), believing some friends or sex partners are taking PrEP (aOR = 1.58, 95%CI = 1.18–2.11), reporting wanting to try CAB-LA if it was more effective than oral PrEP (aOR = 2.05, 95%CI = 1.48–2.86), or believing CAB-LA is more effective than event-driven oral PrEP (aOR = 1.48, 95%CI = 1.10–1.99). This analysis demonstrated Australian GBMSM have a diverse range of preferences of PrEP options, and access to newer options is needed to increase HIV prevention coverage.